Printer Friendly

GENEVA PHARMACEUTICALS AND UPJOHN EXTEND AGREEMENT

 BROOMFIELD, Colo./KALAMAZOO, Mich., March 29 /PRNewswire/ -- Geneva Pharmaceuticals, Inc., and The Upjohn Company (NYSE: UPJ) announced today that the two companies have entered an agreement whereby Geneva will market generic versions of the following Upjohn branded products at later dates: Ansaid Tablets (flurbiprofen), Micronase Tablets (glyburide), and Cleocin-T Topical Solution (clindamycin topical).
 The two companies announced earlier this year an agreement whereby Geneva would market generic versions of Upjohn brands Xanax Tablets (alprazolam) and Halcion Tablets (triazolam) at a later date.
 "This agreement is part of Upjohn's overall strategic plan to take advantage of opportunities in selected generic markets around the world," said Jack J. Jackson, senior vice president for Western Hemisphere Pharmaceutical Operations.
 "For Geneva Pharmaceuticals, this agreement reinforces our commitment to the provision of quality generic products with high levels of service," said Joe Papa, senior vice president of Sales and Marketing.
 Geneva Pharmaceuticals, a subsidiary of the CIBA-GEIGY Corporation, is a leading developer, manufacturer, and marketer of high quality generic pharmaceutical products, headquartered in Broomfield, with distribution capabilities throughout the United States.
 The Upjohn Company is a worldwide, research-based provider of human health care products, animal health products, agronomic and vegetable seeds and specialty chemicals. Headquartered in Kalamazoo, the company has been dedicated to improving health and nutrition for more than a century.
 -0- 3/29/93
 /CONTACT: John P. Lambrechts of The Upjohn Company, 616-323-7076; or David G. Webster of Geneva Pharmaceuticals, Inc., 303-466-2400/
 (UPJ)


CO: The Upjohn Company; Geneva Pharmaceuticals ST: Michigan, Colorado IN: MTC SU: CON

JG -- DE022 -- 0591 03/29/93 14:09 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 29, 1993
Words:262
Previous Article:CHRYSLER AND LAWRENCE LIVERMORE SIGN $6 MILLION COOPERATIVE RESEARCH AGREEMENT
Next Article:ST. LUCIE NUCLEAR UNIT 1 BEGINS REFUELING
Topics:


Related Articles
UPJOHN CONSUMER PRODUCTS DIVISION ENTERS INTO MARKETING AGREEMENT WITH MCNEIL CONSUMER PRODUCTS COMPANY
GENEVA PHARMACEUTICALS AND UPJOHN ANNOUNCE AGREEMENT
,sandi,michi r f bc-Gensia-Upjohn-allianc
UPJOHN TO DEVELOP ANTI-CANCER AGENT FROM JAPAN
SMITHKLINE BEECHAM INTRODUCES NEW FORMULATION OF DYAZIDE; ALSO ANNOUNCES DISTRIBUTION AGREEMENT WITH GENEVA PHARMACEUTICALS
INCYTE AND UPJOHN SIGN $20 MILLION DATABASE ACCESS AGREEMENT
UPJOHN AND GENSIA RESTRUCTURE MULTISOURCE ONCOLYTIC DRUG ALLIANCE
UPJOHN BOARD APPROVES RESTRUCTURED GENSIA AGREEMENT FOR MULTISOURCE ONCOLYTIC DRUG ALLIANCE
CONSUMERS POWER SIGNS LONG-TERM ELECTRIC SALES AGREEMENT WITH PHARMACIA & UPJOHN, INC.
Incyte and Pharmacia & Upjohn Extend and Expand Genomic Database Partnership

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters